ZUMUTOR BIOLOGICS - Trademark Details
Status: 700 - Registered
Serial Number
86921165
Registration Number
5324646
Word Mark
ZUMUTOR BIOLOGICS
Status
700 - Registered
Status Date
2017-10-31
Filing Date
2016-02-26
Registration Number
5324646
Registration Date
2017-10-31
Mark Drawing
4000 - Standard character mark
Typeset
Published for Opposition Date
2017-01-03
Law Office Assigned Location Code
M20
Employee Name
FOSDICK, GEOFFREY A
Statements
Disclaimer with Predetermined Text
"BIOLOGICS"
Goods and Services
Analeptics; Anti-arthritic compositions and preparations; Anti-cancer preparations; Anti-diabetic pharmaceuticals; Anti-diabetic preparations; Anti-inflammatories; Anti-inflammatory and antipyretic preparations; Anti-inflammatory salves; Anti-inflammatory sprays; Antibacterial substances for medical purposes; Antibiotic preparations; Antibiotics; Antidiabetic preparations; Biological preparations for the treatment of oncology, rheumatoid arthritis, diabetes and metabolic disorders; Bone fillers consisting of living materials; Contrast media for in-vivo imaging; Cord blood for medical purposes; Diagnostic agents, preparations and substances for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, oncology, rheumatoid arthritis, diabetes and metabolic disorders; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic media for bacteriological cultures; Diagnostic preparations for medical and veterinary use; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations for medical purposes; Diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic radiopharmaceutical agent for use in PET imaging; Diagnostic radiopharmaceutical preparations; Diagnostic reagents and contrast media for medical use; Diagnostic reagents for medicinal use; Dietetic sugar substitutes for medical use; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of edible wafers for wrapping powdered pharmaceuticals; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in the form of dissolvable films, coatings for tablets that facilitate the delivery of pharmaceutical preparations; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Hypoglycemic agents; In-vivo diagnostic agent used for detection and monitoring of angiogenesis and anti-angiogenic therapy; Insulin; Insulin injectors sold filled with insulin; Medical diagnostic reagents and assays for testing of body fluids; Medical diagnostic reagents for the analysis of body fluids; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicines for the treatment of gastrointestinal diseases; Organotherapeutics; Pancreas hormone preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the prevention of diabetes; Pharmaceutical preparations for the treatment and prevention of metabolic disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of rheumatoid arthritis; Pharmaceutical preparations for treating chemical imbalances; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, elixirs for the treatment of oncology; Pharmaceutical products and preparations to prevent swelling in the legs; Pharmaceutical products for the treatment of bone diseases; Pharmaceutical products for the treatment of joint disease; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Placebo pills for medical use; Preparations for detecting genetic predispositions for medical purposes; Probiotic supplements; Protein arrays for medical diagnosis purposes; Radio-isotope markers for therapeutic or diagnostic use; Radioactive pharmaceutical preparations for use in vivo diagnostic or therapeutic use; Radioactive substances for use in nuclear medicine; Radiopharmaceutical imaging and detection agents for diagnosing and monitoring cancer; Reagents and media for medical and veterinary diagnostic purposes; Surgical implants comprised of living tissues; Syrups for pharmaceutical purposes for the treatment of oncology, rheumatoid arthritis, diabetes and metabolic disorders; Tumor suppressing agents
Goods and Services
Bacteriological research; Biochemical research and development; Biological research; Biotechnology research; Chemical, biochemical, biological and bacteriological research and analysis; Conducting early evaluations in the field of new pharmaceuticals; Development of pharmaceutical preparations and medicines; Laboratory research services relating to pharmaceuticals; Medical research services in the field of cancer; Pharmaceutical drug development services; Pharmaceutical product evaluation; Pharmaceutical research and development; Pharmaceutical research services; Product development consultation; Product development for others; Product research; Research and development of vaccines and medicines; Research in the field of chemistry; Research on the subject of pharmaceuticals; Scientific research consulting in the field of oncology, rheumatoid arthritis, diabetes and metabolic disorders; Scientific research for medical purposes in the field of oncology, rheumatoid arthritis, diabetes and metabolic disorders; Scientific research in the field of genetics and genetic engineering; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy
Classification Information
International Class
042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services. - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software; legal services.
US Class Codes
100, 101
Class Status Code
6 - Active
Class Status Date
2016-03-02
Primary Code
042
First Use Anywhere Date
2015-06-22
First Use In Commerce Date
2016-08-01
Current Trademark Owners
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
30 - Original Registrant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
CHATTERJEE SOHANG
Address
Please log in with your Justia account to see this address.
Trademark Events
Event Date | Event Description |
2016-03-01 | NEW APPLICATION ENTERED IN TRAM |
2016-03-02 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2016-06-10 | ASSIGNED TO EXAMINER |
2016-06-10 | NON-FINAL ACTION WRITTEN |
2016-06-10 | NON-FINAL ACTION E-MAILED |
2016-06-10 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
2016-10-28 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2016-11-08 | ASSIGNED TO LIE |
2016-11-22 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2016-11-22 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2016-11-23 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2016-11-29 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
2016-12-14 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2017-01-03 | PUBLISHED FOR OPPOSITION |
2017-01-03 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2017-02-28 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2017-08-28 | TEAS STATEMENT OF USE RECEIVED |
2017-09-14 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2017-08-28 | USE AMENDMENT FILED |
2017-09-20 | STATEMENT OF USE PROCESSING COMPLETE |
2017-09-26 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
2017-09-27 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
2017-10-31 | REGISTERED-PRINCIPAL REGISTER |